Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
D Ross CamidgeDaniel MorgenszternRebecca S HeistMinal BarveEverett E VokesJonathan Wade GoldmanDavid S HongTodd M BauerJohn H StricklerEric AngevinMonica MotwaniApurvasena ParikhZhaowen SunBruce Allen BachJun WuPhilip B KomarnitskyKaren KellyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Teliso-V monotherapy was tolerated and showed antitumor activity in c-Met+ NSCLC. On the basis of overall safety, pharmacokinetics, and efficacy outcomes, 1.9 mg/kg Teliso-V once every 2 weeks and 2.7 mg/kg once every 3 weeks schedules were selected for further clinical development.
Keyphrases
- combination therapy
- tyrosine kinase
- cancer therapy
- small cell lung cancer
- open label
- gestational age
- single cell
- cell therapy
- clinical trial
- advanced non small cell lung cancer
- drug delivery
- randomized controlled trial
- hodgkin lymphoma
- mesenchymal stem cells
- skeletal muscle
- insulin resistance
- preterm birth
- brain metastases